FDA Clears BD200, a Cancer Drug That Switches Targets When Tumors Dodge

Biolojic Design says the FDA has cleared an Investigational New Drug application for BD200, opening the door to the first-in-human trial of what the company calls the first multibody drug conjugate. Founder and CEO Yanay Ofran said enrollment in a global Phase 1 study should start

The drug is built to dodge the failure mode that has dogged antibody-drug conjugates for decades: tumors shedding the protein the drug aims at. Standard ADCs lock a Y-shaped antibody onto one target and tow a cytotoxic payload behind it. When a cancer cell stops displaying that protein, the antibody can't bind, the payload never lands, and antigen-negative tumor cells survive and repopulate.

BD200's arms each recognize either Trop2 or Nectin-4 — two proteins overexpressed across solid tumors including triple-negative breast cancer, urothelial carcinoma and lung cancer. If a tumor drops Trop2, both arms can swing to Nectin-4, and vice versa. That's different from a fixed bispecific ADC, where one arm is permanently assigned to each target: losing one costs the molecule 50 percent of its binding, while Biolojic's format redeploys full binding capacity to the surviving target. Chief medical officer Roger Waltzman framed it as flexible binding built to clear those hurdles.

Both targets already have approved drugs behind them. Trop2 is the target of sacituzumab govitecan (Trodelvy) and datopotamab deruxtecan (Datroway), while Nectin-4 is targeted by enfortumab vedotin (Padcev). The dual approach is partly defensive: Nectin-4 downregulation has been documented as a resistance route for enfortumab vedotin-based therapy, and Trop2 negativity shows up in roughly 6.5 percent of urothelial carcinoma patients, with low expression in another 22 percent. BD200 carries a topoisomerase I inhibitor payload, the same class used in Trodelvy and Datroway, which brings a bystander effect that can also hit neighboring antigen-negative cells.

The cleared Phase 1 is a safety study in patients with select solid tumors known to express Trop2 and Nectin-4, measuring safety, tolerability and pharmacokinetics alongside early efficacy signals. After dose-finding, Biolojic plans to pick optimal biologic doses, narrow to specific tumor types and explore monotherapy plus combinations. Preclinical data presented at the American Association for Cancer Research annual meeting in April 2026 showed BD200 beating standard monospecific ADCs and a template bispecific ADC in tumor models — company-reported results that have not been confirmed in patients. Enrollment targets, NCT numbers and dosing details weren't disclosed.

One limit worth flagging: BD200 only addresses resistance at the antigen-availability layer. A 2026 review mapped at least seven ways cancers defeat ADCs, from impaired internalization and drug efflux pumps to lysosomal acidification and apoptotic pathway changes, and noted resistance rarely comes from a single defect. Beating those would take combination partners, different payloads or new linker chemistry — not this molecule alone.